With our partner Salesforce, unify sales, marketing and customer service. Accelerate your growth!
Managing scientific and regulatory documentation is a major challenge for the pharmaceutical industry, where each delay can delay the release of treatments to the market and de facto slow down patient access to life-saving treatments. To address this issue, Biolevate, a Parisian startup, offers ELISE, a platform that uses artificial intelligence to transform the way medical documents are created, managed and optimized.
Founded in 2023 by Joël Belafa (CEO)former Dataiku executive and expert in AI for businesses, Nathan Chen (COO)ex Coloplast, and Anas Laaroussi (CTO) And Antoine De Torcy (CPO), the team combines expertise in artificial intelligence and in-depth knowledge of pharmaceutical processes.
ELISE: AI at the service of scientific documentation
The platform ELISE (Elevate Literature Intelligence for Scientific Excellence) uses advanced technologies like natural language processing (NLP) and computer vision to optimize every stage of the document lifecycle.
Key features include:
- Generation of compliant documents: reduced risk of regulatory errors.
- Documentary research and monitoring: rapid identification of critical information in scientific literature.
- Collaboration and monitoring: integration of feedback and tracking of modifications for smooth project management.
- Automated analysis: metadata extraction, compliance checking and potential risk prediction.
This AI-based approach guarantees traceable results thanks to a “human-in-the-loop” system, allowing users to validate and understand each decision generated by the platform.
Fundraising to accelerate development
To support its ambitions, Biolevate announces that it has raised 6 million euros in a Seed financing round led by EQT Ventures. This financial support will allow the startup to expand its team, strengthen the technological development of the ELISE platform and establish itself in new strategic markets.
